MVM: Autoantibodies, Endomysial(Tissue Transglutaminase): FDA Product Code 510(k) Clearances, Predicate Lineage, and Recall History (1998 to 2021)

U.S. FDA CDRH three-letter product classification MVM in Immunology (21 CFR 866.5660) reconciled across 1998 to 2021.

Review 40 FDA 510(k) clearances, 1 recalled K-numbers, and 1 cumulative 1976 to 2026 CDRH recall notices for MVM: Autoantibodies, Endomysial(Tissue Transglutaminase) on Predicate Ledger.

Reconciled U.S. FDA 510(k) and Recall Summary for MVM: Autoantibodies, Endomysial(Tissue Transglutaminase)
Regulatory MetricVerified Value
Entity ClassificationFDA 3-Letter Product Code (MVM, Class 2)
Clinical Advisory SpecialtyImmunology (Panel IM)
Cleared FDA 510(k) Submissions (1976 to 2026)40 clearances (18 California, 45.0%)
Cleared 510(k)s Linked to a Recall Notice1 K-numbers (2.50% of cleared cohort)
Cumulative Historical Recall Notices (1976 to 2026)1 notices (0 Class I, 1 Class II, 0 Class III)
Currently Open vs Historical Recall StatusCumulative 1976 to 2026 FDA archive total (1 notices); verify live open vs terminated status per notice in dossier
Implantable and Life-Sustaining Clearances0 implantable (0.0%) and 0 life-sustaining
Median FDA 510(k) Review Duration121 days (90th percentile: 287 days)

Cumulative recall counts span 1976 to 2026 across U.S. FDA CDRH and openFDA public archives and combine closed historical notices with any currently open field actions. Browse all device cohorts, 20 clinical specialties, Shared 510(k) Predicate Lineage Stage, or reconciliation methodology.

Meru AI Healthcare Data Engineering: Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI → · AI for Healthcare Practice · Healthcare Price & Patent-Cliff Crosswalk Guide.